Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OH2 + Capecitabine Maintenance in Advanced Colorectal Cancer
NCT05648006Phase 2Terminated
- Sponsor
- Wuhan Binhui Biopharmaceutical Co., Ltd.
- Start
- Oct 2023
- Primary completion
- Apr 2024
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of OH2 in colorectal cancer (CRC), sponsored by Wuhan Binhui Biopharmaceutical Co., Ltd.. Started Oct 2023; status: terminated.
02
Drugs
OH2
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05648006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05648006.